IP Library Granted Patent US 8,173,671
Granted Patent B2
US 8,173,671 · App. 12/967,250 · Granted May 8, 2012

Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,671
App. No.
12/967,250
Granted
May 8, 2012
Kind
B2
Abstract

Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.

Claims (10)

1. A method of treating an otic infection comprising topically administering to the ear a solution composition consisting essentially of

a) 0.545% (w/v) moxifloxacin hydrochloride;

b) 0.11% (w/v) dexamethasone sodium phosphate;

c) 0.01% (w/v) edetate disodium;

d) 0.5-0.75% (w/v) sodium chloride;

e) 0.3% (w/v) boric acid;

f) 0.01% (w/v) benzalkonium chloride;

g) 0.05% (w/v) tyloxapol;

h) NaOH or HCl in an amount sufficient to cause the composition to have a pH from 7.8-8.0; and

i) water.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS. PREVIOUSLY RECORDED AT REEL: 050746 FRAME: 0431. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.. Recorded Oct 18, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050767/0001 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Oct 17, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050746/0431 →
MERGER Recorded Oct 16, 2019
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 050735/0465 →